Phase 1 Open Label, Multicenter Study of MK-1454 Administered by Intratumoral Injection as Monotherapy and in Combination with Pembrolizumab for Patients with Advanced/Metastatic Solid Tumors or Lymphomas
A study for patients with advanced solid tumors or lymphomas using study drug MK-1454
Sponsor: Merck Sharp & Dohme Corp.
Enrolling: Male and Female Patients
IRB Number: AAAR1107
U.S. Govt. ID: NCT03010176
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: This is a research study to test a drug MK-1454 that has not been approved for sale. Pembrolizumab (MK-3475) has been approved for use in certain types of melanoma, lung cancer, and head and neck cancer however it has not been approved for lymphoma. The purpose of this study is to test the safety and tolerability of the research study drug MK-1454 and to find the highest dose of MK-1454 that can be given alone or in combination with pemrolizumab with the least risk of serious side effects.
This study is closed
Investigator
Matthew Ingham, MD
Do You Qualify?
Have you been diagnosed with an advanced solid tumor or lymphoma? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE